乳腺癌蒽环类新辅助化疗疗效及ER、PR、HER2表达关系.docVIP

乳腺癌蒽环类新辅助化疗疗效及ER、PR、HER2表达关系【摘要】 目的 探讨乳腺癌蒽环类新辅助化疗疗效与ER、PR、HER2表达的关系。方法 乳腺癌患者在接受蒽环类方案新辅助化疗前用免疫组化法检测乳腺癌组织中ER、PR和HER2的表达情况，新辅助化疗3周期结束后进行疗效评价，分析它们之间的关系。结果 ER和PR阴性表达组47例，有效率为80.85％；其中PCR率为23.40％。ER和(或)PR阳性表达组43例，有效率为60.47％；其中PCR为6.98％。两组有效率及PCR率比较，差异有统计学意义（?P?0.05）。结论 激素受体双阴者可能较单阳或双阳者对蒽环类方案化疗的敏感性更高。尤其是激素受体双阴者的PCR率明显高于单阳或双阳者。? 【关键词】 乳腺癌； 蒽环类； 新辅助化疗； ER； PR； HER2?? The relationship between expression of ER, PR and HER2 in breast cancer patients with the efficacy of anthracycline neoadjuvant chemotherapy ?WANG Yi-li，XIONG Qiu-yun.No 3 Hospital of Nanchang, Nanchang 330009,China?? 【Abstract】 Objective To study the relationship between expression of estrogen receptor(ER), progesterone receptor (PR) and HER2 in breast cancer patients with the efficacy of anthracycline neoadjuvant chemotherapy.Methods The ER, PR and HER2 expression situation in the patients with breast cancer were examined immunohistochemically before the operation were treated with anthracycline neoadjuvant chemotherapy. And the response was evaluated after 3 circles and the correlation between them was analysed.Results In 47 patients with ER and PR absent, the response rates is 80.85% and the PCR rates is 23.40%. In 43 patients with ER or PR positive tumors, the response rates is 60.47%， and the PCR rates is 6.98%. Compared the response rates of the two groups and the PCR rates of the two groups,there is significant difference(?P?0.05).Conclusion Breast cancer with ER and PR absent may be more sensitive to anthracycline neoadjuvant chemotherapy. Especially, the PCR rate of the patients with ER and PR absent is obviously higher than the patients with ER and PR positive tumors.? 【Key words】 Breast cancer； Anthracycline; Neoadjuvant chemotherapy； Estrogen receptor； Progesterone receptor； HER2 ?? 乳腺癌是最常见的妇女恶性肿瘤之一，随着新辅助化疗的日益广泛应用，其治疗效果对于患者预后的预测作用越来越受到人们的关注。临床上能否找到预测新辅助化疗疗效的指标已成为临床关注的重点。蒽环类方案是最常用的乳腺癌化疗方案之一，因其疗效确切和价格相对便宜故广泛地运用于乳腺癌的新辅助化疗中。乳腺癌细胞中雌孕激素受体（ER、PR）、人类表皮生长因子受体（HER2）的表达对患者的预后有很重要的意义。目前国外对术前蒽环